CATUG, specialises in integrated nucleic acid and drug delivery CRDMO services and Crystal Bio a member of Crystal Pharmatech, have announced a partnership, marking a significant milestone in the field of nucleic acid analysis. The collaboration has led to the launch
Charles River and Wheeler Bio have announced the completion of an agreement that promises to accelerate the journey from discovery and CMC development to manufacturing. This collaboration aims to streamline the process, reducing the time and resources required to transition from the discovery
AtomVie Global Radiopharma, a radiopharmaceutical contract development and manufacturing organisation (CDMO), has announced a strategic collaboration with RLS & UPPI. The partnership is aimed at strengthening AtomVie’s existing radiotherapeutic distribution network in the United States. The collaboration comes at a
Bernardo Estupiñán has a career spanning chemistry and business development, and now working as a consultant to guide companies developing new biopharmaceuticals through contract manufacturing. In this interview he shares his advice for how biotechs can successfully navigate the contract
Analysis by Stifel reveals the ratio of market value per employee among the world’s top 30 pharma companies, by market cap. The analysis shows that: Source: Stifel
Genezen, a prominent player in the cell and gene therapy Contract Development and Manufacturing Organisation (CDMO) sector, announced today that it has licensed the Cytegrity™ proprietary stable production system from biotechnology leader CSL. The Cytegrity™ system is an advanced inducible
National Resilience, a technology-focused biomanufacturing company, has announced a significant investment of $225 million into its Ohio facility. By 2025, it aims to produce more than 200 million units across its network for various types of treatments, including the widely
Prices of pharma R&D and clinical trials are expected to increase due to a tight labour market with an ongoing shortage of qualified and experienced researchers. In addition, prices for Non Human Primates (NHPs) are currently 10x pre-COVID-19 levels.
INCOG BioPharma Services, a Contract Development and Manufacturing Organisation (CDMO), has announced a significant expansion in its production capacity. The company has added an impressive 100 million units to its syringe and cartridge capacity. The upcoming summer will see the
Mikart, the contract manufacturer has announced the addition of state-of-the-art Fette double-sided tablet presses to its manufacturing operations. This strategic investment is set to bolster Mikart’s production capacity and cater to the product demands of its growing client base. The Fette
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
